Dr. Johnson Lau
Chief Executive Officer
Replay available
Athenex (ATNX) Q2 2021 earnings call, held 2021-08-05. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/athenex-inc-atnx-q2-2021-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good morning, and thank you for joining our conference call. Today, we will provide an update on Athenix's business. as well as a review of financial results for the second quarter of 2021. The news release detailing the results crossed the wire earlier this morning and is available on the company's website. A replay of this call will also be archived on the company's website. During the conference call, the company will make projections or forward-looking statements regarding future events, including statements about financial, business, and clinical milestones anticipated in fiscal year 2021 and beyond.
0:57 We encourage you to review the company's past and future filings with the SEC, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements. You can find our SEC filings in the EDGAR database at www.sec.gov or in the Investor Relations section at our website at www.athenix.com. This morning we are joined by Dr. Johnson Lau, Chief Executive Officer, Mr. Jeff Yorden, Chief Operating Officer, Dr. Rudolph Kwan, Chief Medical Officer, Mr. Randall Zee, Chief Financial Officer, and Dr. Dan Lang, President of the Phoenix Cell Therapy. The management team will be available to answer questions after the prepared remarks.
1:44 I will now turn the call over to Johnson for introductory comments. Johnson?
1:50 Thank you, Tim. There were several important developments and a phoenix in the second quarter that I would like to cover this morning. I want to discuss the progress we have made with the FDA on Oropacetaxel plus Enzequeda, the ongoing commercialization of this theory, as well as the recent QA therapeutics acquisition, which is part of an ongoing plan to build a presence in cell therapy. During the second quarter, We held a Type A meeting with the FDA to discuss the deficiencies that had been raised in the complete response letter we received in February. The FDA encouraged us to continue development of olpraclitaxel for the treatment of metastatic breast cancer.
2:42 A key topic at the meeting was how we can potentially address the deficiencies raised in the CRL. We are now evaluating the option of conducting a new clinical study and working on the optimal design for such a study that we plan to present to the FDA later this year. We are very conscious, of course, about the capital and time requirements. Ultimately, we hope there is a path that we can agree on that is viable and that will result in better creation for our stakeholders. Dr. Rudolph Kwan, our Chief Medical Officer, will provide more details later.
3:29 We continue to believe that Oropracotexel has demonstrated a very strong and compelling clinical profile, and that it offers superior efficacy and safety compared with IV Pracotexel. If approved, we intend to position it as the chemotherapy of choice in metastatic breast cancer. As we consider our strategy for the metastatic breast cancer indication, it is important to remember that we have other programs evaluating oral pachytexel in additional indications and in combination with other therapies. This includes our angiosarcoma study the combination with prembolizumab study, and the iSpy2 trial.
4:24 Again, Dr. Kwan will provide more details later. Kisiri, or terpenibulin ointment, our first-in-class microtubule inhibitor for the treatment of epidemic keratosis of the face or scalp, launched in the U.S. in February, led by our partner, Amral. Amaral provided an update on the launch progress on their most recent earnings call. Their main focus at this point in the launch is on gaining payer coverage in the U.S. to drive sales volume. We are delighted to see that Kisiri continues to gain market share in the AT market, and that feedback from patients and dermatologists has been positive.
5:18 Amaral highlighted the need for new therapies like ours, given that existing topical therapies are associated with significant side effects. We are also pleased to report that Amaral recently received approval from the European Commission to market the series in Europe. This is another important milestone that will bring a new and innovative treatment option to more AK patients. Amaral is preparing for the launch in Europe, expected in second half of this year. We announced in July that we have signed additional license agreements to commercialize Casiri.
6:05 Siparis, a subsidiary of CSL, will market the product in Australia and New Zealand. And Avea Pharma is our partner in Canada. These new agreements are part of the game plan to develop a global presence for Kisiri and to extend access to more patients around the world. Phoenix now has strategic partnerships for terpidipaline in place in major markets, including North America, Europe, Australia, Japan, and China. In May, we acquired Cure Therapeutics.
6:50 Cure has developed a potential first-in-class NKG cell therapy treatment for neuroblastoma as well as an allogeneic platform for hematologic and solid medical disease based on technology licensed from the Data College of Medicine. In the near term, the acquisition provides a Phoenix with two attractive assets with solid clinical data and potential additional data readouts over the next 12 to 18 months. Importantly, there is also an opportunity to combine allogeneic NGT cells with our TCLT cell therapy in solid tumors. Acquiring CURE is a strategically important move for iFINEX and consistent with our mission to bring innovative cancer treatments to patients.
7:47 is becoming increasingly recognized in the medical and scientific communities that cell therapy holds the promise of being a game-changer in the treatment of cancer. Dr. Dan Lang, our President of Atheist Cell Therapy, will provide an update on TUA and discuss in progress makes sense we make this acquisition. There's also a management update I want to discuss. We have announced that Mr. Randall Zee, our chief financial officer, has given us notice that he will be leaving APNX. Randall has made a decision to return to the financial sector.
8:33 We'll be initiating a formal search for a replacement CFO. In the meantime, Mr. Stephen Adams, our corporate controller, will take on the role of Interim Chief Accounting Officer. Steve has been with a Phoenix since 2009, and he is very familiar with all aspects of our business. His financial function is in very capable hands. Randall has been a valuable member of the team, and I want to thank him for his contributions and wish him well in his next position. Cash at the end of second quarter was $146.7 million.
9:20 As stated previously, we continue to assess very carefully about how to utilize and manage our resources efficiently and conserve cash. Our current priorities are to maximize the growth potential for our orthoscopsy and cell therapy programs while supporting our APS-APD business. Coupled with prudent cash management, we continue to review our financing options opportunistically, as you will learn more from Randall in the discussion on our financials. We will evaluate all scenarios for our business and remain focused on maximizing value for our shareholders.
10:08 With that, I will turn the call over to Dr. Rudolph Kwok.
10:13 Thank you, Johnson. Let me provide some more detail on the Type A meeting we held with FDA on oral Placatexel. We prepared extensively ahead of this meeting and used our time to discuss the deficiencies raised in the CRL. The FDA was supportive and encouraged us to continue to develop oral Placatexel in metastatic breast cancer. They reiterate that a well-conducted trial may adequately address the deficiencies. As Johnson mentioned, we are thinking carefully about the design of a new trial and want to collect additional overall survival data this year.
11:05 We expect that we'll be ready to share our proposed trial design with the agency in the fourth quarter. We plan to provide a further update around that time. As Johnson indicated, we are also prioritizing our oral practical program in angiosarcoma and intend to discuss a registration pathway with the FDA. We have completed enrollment of 43 patients in our ongoing phase two trial. As a reminder, we previously reported interim data at ESCO last year that showed complete and partial response rates of 27% and 23%, respectively, in the 22 invariable patients at that time.
11:59 Angiosarcoma is a disease with limited treatment options and for which oral Patexo has received often drug destinations. We will provide an update once we have clarity from the FDA on next steps. As to our phase one study of Oroplactatexel in combination with Pembrolizumab study in solid tumors, the dose finding results from this study will be presented at the ESMO virtual conference taking place in September. Our abstract has been accepted for e-poster presentation. We are currently proceeding into the expansion phase of this study for the cohort of lung cancer patients, with plans to expand into a second cohort of gastric cancer patients.
12:57 Lastly, on the I-SPI-2 trial, in which oral plethotaxel is being studied in combination with GlaxoSmithKline's dosteramab and carboplastin for neoadjuvant treatment in breast cancer. This trial is ongoing and progressing well. I will now let Dr. Dan Lang provide an update on our cell therapy programs.
13:26 Thank you, Rudolf. Our acquisition of Keurig Therapeutics was part of a major strategic initiative We believe our NKT cell technology is well positioned in the cell therapy landscape. because NK T cells possess properties and attributes that may prove to be better than T cells or NK cells. Unlike conventional T cells that could cause GVHD, NK T cells don't have the classical TCRs which render the risk of GVHD minimal.
14:15 NK cells typically have limited expansion potential following activation and can be difficult to cryopreserve. Conversely, NKT cells have tremendous expansion potential both in vitro and in vivo, and exhibit excellent stability and functionality following cryopreservation. NKT cells can also home to tumors and solid tissue, making them an ideal platform to attack solid tumors. Lastly, NKT cells play an important role in propagating and amplifying the immune response by bridging the innate and adaptive immune systems. Since announcing the acquisition, there has been smooth integration of the team and operations, which has benefited from synergies with the existing of Phoenix Cell Therapy infrastructure.
15:11 We have been actively working to convert the cure academic INDs at Baylor to meet all regulatory requirements of an industry IND. which will allow us to scale up and expand the current single center trial across multiple study sites and accelerate patient enrollments. The construction of our cell manufacturing facility in Buffalo is complete. We expect to begin running validation batches in the second half of the year with the aim of having the capability to support our Phase I studies. CURO501 is the autologous cell therapy product currently in a Phase 1 study in patients with relapsed or refractory neuroblastoma, known as the GINAKIT-2 trial. We have now dosed up to cohort level 4 out of a total of 6 cohorts.
16:07 We recently presented this data at ASGCT, where we disclosed one complete response, one partial response, and 4 patients with stable disease out of 11 evaluable and heavily pretreated pediatric neuroblastoma patients. CURA 502, our allogeneic product, is being evaluated in a Phase I trial in patients with CD19-positive relapsed or refractory lymphoma and leukemia, known as the ANCOR trial. As we discussed at the time of the CURA acquisition, we observed one partial response and one complete response in the first two patients treated at the lowest dose level. We will be submitting an abstract on this study, which will include use safety and efficacy data to the ASH annual meeting.
17:02 The next cell therapy candidate to enter the clinic will likely be CURE503, another allogeneic product targeting GPC3 in hepatocellular carcinoma. We plan to submit an IND in 2022. In our TCRT program, we have initiated our Phase I NYESO trial and are expected to begin enrollment this quarter. The study is testing an autologous, high-affinity PCR T-cell therapy, and we are screening patients with the NYESO1 antigen, which is expressed on a variety of solid tumors. Because NKT cells can express and kill tumors through engineered TCR transgenes, we are excited about the opportunity to merge our TCRs and NKT platforms and anticipate providing more news on this in the future.
17:57 In summary, there are significant cell therapy clinical activities ongoing at the Phoenix, two studies with NKT cells and one with our highest-energy PCR team. We look forward to generating important clinical data and sharing the transformative potential of our cell therapy platform with the medical community. I will now turn it over to Jeff.
18:22 Thank you, Dan. We generated product sales of 21.4 million in the second quarter compared with 40.2 million in Q2 of 2020. As we called out previously, there was 14 million in non-recurring revenues sold to other countries in Q2 2020. And that is a major reason for the difference in the sales results between the two quarters. In addition, in the first half of this year, there have been significant COVID-related challenges in our Indian supply chain, and to a lesser extent, in China. As a result, we were not able to receive inventory from these regions for a certain period of time.
19:13 Other issues that are relevant include the fact that the company experienced a higher amount of product sales in 2020 as we started fulfilling demand for certain drugs used to treat patients hospitalized with COVID and demand for FDA shortage products. The product revenues in the second quarter of last year were particularly high given the COVID pandemic had just started. We anticipate that there will be several factors that will increase product sales in the second half of 2021. These factors include new product introductions, better inventory positions as the COVID pandemic improves in India and China, improvement in shipping options from India and China, potential sales of shortage products, new wave of COVID related cases will increase sales of both APD and APS, increased capacity in Q4 for APS and continued sales improvements in a few key APD products.
20:29 Athenix Pharmaceutical Division currently markets 34 products with 61 SKUs, and Athenix Pharma Solutions markets four products with 16 SKUs. Construction of our facility in Dunkirk, New York, is essentially complete. We have built eight dedicated bays for the expanded 503b business and plan to commence manufacturing there in Q4 2021. Our current capacity at our clearance facility is fully utilized and these new bays will substantially increase our capacity. I will now turn the call over to Randall to discuss the financials.
21:19 Thank you, Jeff.
21:21 I will go through a few key financial updates for the second quarter. Revenues from product sales in Q2 were $21.4 million compared with $40.2 million for the same period last year. As Jeff mentioned, product sales this quarter were affected by a decrease in demand for COVID-19 related drugs compared to last year. In the second quarter of 2020, the COVID pandemic just started. And we also recorded some significant non-recurring orders of approximately 14.1 million. In the first half of 2021, we also experienced COVID-related challenges in our Indian and China supply chains, affecting the amount of inventories we could receive from our partners in these regions.
22:08 For the second quarter, we recorded approximately 500,000 of license fees and other revenues which included royalties received from Amro on Kyceria sales in the U.S. Cost of sales for the second quarter totaled $19.7 million, down from $33.3 million a year ago. The decrease was primarily due to a decrease in cost of APB product sales, generally in line with the decrease in its revenue. R&D expenses for the second quarter totaled $21.1 million, compared to 22 million a year ago. This was primarily due to a decrease in respiratory costs, clinical operations, and preclinical operations.
22:55 The decrease in these items was partially offset by increases in aripacetaxel and Asequadar API costs, and preparation for product launch, together with increases in drug licensing costs, R&D-related compensation expenses, costs related to 503 and cell therapy development. SG&A expenses for the second quarter totaled $21.2 million, an increase from $17.5 million a year ago. This was primarily due to increases in professional fees and other expenses related to the CURR acquisition, as well as an increase in compensation-related costs and operating costs. These increases were partially offset by a decrease in costs for preparing to commercialize Oropacotaxel as significant prelaunch activities occurred in 2020 and slowed down upon receipt of the CRL in February 2021.
23:55 In Q2, we recorded an income tax benefit of $11 million versus an income tax expense of $21 million in the same period last year. The tax benefit is in connection with the PER acquisition that took place in May. Net loss attributable to a Phoenix for the second quarter was $34.3 million, or $0.33 per diluted share, as compared to a net loss of $40.5 million, or $0.50 per diluted share for the same period in 2020. In terms of product sales guidance, as before, we are limiting financial guidance to the existing Athenex product portfolio only. In 2020, we recorded a significant amount of revenues from international customers as a result of the global pandemic.
24:46 We do not see these revenues as recurring in nature, while at the same time, we continue to expand our product portfolio. We are now affirming the guidance we provided on May 6, 2021, and currently expect that product sales in 2021, excluding any royalties from Kiseri sales, could be in line with 2020 levels. As of June 30, 2021, At Phoenix had cash, cash equivalents, restricted cash, and short-term investments of $146.7 million. Since receipt of the CRL earlier this year, we have started putting cash preservation measures in place, which include deferring commercialization-related expenses and slowing down certain clinical programs to after we have more clarity from the FDA.
25:39 As a result, we believe our cash will get us into the fourth quarter of 2022. Finally, as Johnson mentioned, I have tendered my resignation as CFO. The past four years have been a tremendously exciting period at Phoenix, and it has been great to see the company evolve and achieve a number of major milestones. It has been especially rewarding to have played a role in helping to advance and bring to market innovative cancer treatments. I'm very grateful for the opportunity to have worked with the Phoenix Board and management team, as well as all of our investors and corporate partners during my tenure. For further details on our financials, including results for the six months and June 30, 2021, I will refer you to our Form 10-Q to be filed with the SEC.
26:34 I will now turn the call back to Johnson for closing comments.
26:39 Thank you, Randall. As you have heard from the other members of the team, there are a lot of developments at APNICs today and multiple opportunities to create value. We are thinking carefully about our overall strategy and are running scenarios across all of our divisions to determine how best to manage resources. This will be in tandem with careful evaluation of returns on our scientific and business activities. Regarding oral pachytexel in metastatic breast cancer, we are certainly pleased that the FDA is supportive of our continued development. At the same time, we want to be realistic and recognize that conducting another large multi-year study in breast cancer may not be the best use of capital.
27:33 will continue to work on designing an optimal trial that addresses the deficiencies in the CRL and explore additional pathways. We firmly believe that Oropraclitaxel has some compelling clinical profile and can potentially address significant medical needs in multiple indications. We look forward to providing further updates. We will now open the call for questions. Thank you. At this time, we'll be conducting a question and answer session. If you'd like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue.
28:21 For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question comes from the line of Robin Kornoskis with Truist Securities. Please proceed with your question. Hey guys, this is Kripa on the line for Robin. Thank you so much for taking my question. Can you, I know you mentioned that if it's a large controlled trial, you will have to think about it, but can you maybe provide some more clarity on what the bookends are in terms of how big a trial would you go forward with and what What additional color did you get from the FDA that can help you decide what sort of a trial you would need to design?
29:14 And as far as the timeline is concerned, is the 4Q settled? Is there any additional communication you might have with the FDA in between now and before you submit the design to the FDA? Thank you.
29:29 Rudolf?
29:31 Yeah, thank you for your questions. It is premature to discuss the timing or the scope of the study until we have the chance to agree with the FDA. I think that will determine what it is. I would also say that the FDA basically reiterate the request of their proposal for a well-conducted study, and the focus is on safety. So between now and the fourth quarter, we intend to submit a proposal and have the FDA input. So once we have that input, we will disclose the design. Does that answer your question?
30:26 Yeah, exactly. Thank you. And then one follow-up question. So how many patients of data will we see at ESMO and what sort of duration they would be on? Can you maybe provide any color on what to expect at ESMO?
30:42 Yes. We completed 40 enrollment of 43 patients and of course not all of them would have completed study at the time of ESMO. So you'll expect to see A lot more than the 22 patients we present in ASCO, but not quite the full 43 patient subset. Great. Thank you. Thank you. Our next question comes from the line of Omar Rafat with Evercore ISI. Please proceed with your question.
31:18 Hi. Thanks so much for taking my question. I have three quick ones, if I may. First, I guess, why not do an aggressive refiling? It sounds like you have to run a trial anyway, so why not do that in the context of various decisions FDA has been making in other divisions? Secondly, for this well-conducted study you do have in mind, do you think you could have interim data in second half next year? And I ask because the febrile neutropenia signal was all in the first 8 or 12 weeks from what I recall, so wouldn't you have that very fast? And then finally, I feel like there's a regulatory reason to run a study, but then more importantly, there's a commercial reason to run the study too, whereby you could establish yourself against sort of the true competitor in the market, which is capicidabine. And I wonder why not run a mid-sized trial versus capicidabine, not just for regulatory reasons, but really to solve for the ultimate issue, which is commercial positioning. Thank you.
32:16 Thank you. Uma, Rudolf?
32:20 Uma, can you repeat your first question?
32:23 The first question is whether we should consider a more aggressive refining of the NDA instead of current discussion with FDA.
32:36 Uma, certainly we are looking at all options. What we reiterate that the FDA is very encouraging and supportive of development in the breast cancer indication, they also reiterate their request for a new study in the US. So we take all those into consideration, and certainly aggressive refining is still one thing that we'll consider, but we have to consult with the FDA as to whether that will be acceptable to them. So I think that's all I can say at this time point.
33:24 Regarding the timing of the second quarter, you are absolutely correct that the more serious fat-bound neutropenia does occur early, and we believe we have addressed that issue in the pivotal study, although the FDA would like to pre-specify study in the U.S., and that's what we will be carefully looking at. So timing, it will depend on the ultimate design, but certainly that important safety signal is correct in occurring in the early part of the study. Regarding the commercial aspect, certainly having a study in the U.S., as the FDA indicated they want, it certainly would have in the eventual commercialization.
34:23 That's the audio.
34:26 I guess, would you have data from this study you have in mind in second half 22?
34:33 I think it's too early to define that study. It depends on the design that is acceptable to the FDA. And certainly, depending on the scope and the design, there could be interim readout, but I cannot really go more into that until we have an agreement with the FDA.
34:56 I guess maybe asked a different way, the complete response was back on March 1st, and it was very clear that it's heading towards some sort of a trial for submission. And what I'm trying to figure out is, Have we lost time? Should we not have initiated a mid-size randomized trial in second quarter instead of having to wait for FDA to tell us whether a single alarm is acceptable or not? And I say that because that type of mid-size randomized trial was likely very relevant, not just for regulatory but also commercial, and it would have answered all these questions.
35:31 I think it's easy to consider different alternatives. I think the The question is where to go to an agreement with the FDA, what is required. On the one hand, we explore a more aggressive refining with our new study. On the other extreme, one could interpret the FDA want a repeat of a phase three program. So it is a dialogue that we are ongoing with the FDA. We should just say that I think we have a bit more clarity as to what the FDA focus on, which is safety, and they have not, and they have focus on repeating is a well-conducted study in the U.S., and that is what we are working towards with them.
36:23 So I would not speculate whether we lost time or gained time or whether we have the, what way to go retrospectively. Does that help?
36:36 Omar, let me add some color here. Your questions are very good with regard to O4 strategy, but it's always important to remember that we are working very closely with FDA. Respect to regulatory authorities and working closely with them is actually a very important approach that we are adopting. We respect their opinion and we're working with them together to resolve the differences in the interpretation of the data. And certainly, I mean, there are a range of studies that we can provide, and then for some of the best-case scenario, certainly we'll have some safety signal already by the second half of next year. That, I think, is the case in case FDA accepts our most ideal study design. I think that hopefully answers your question.
37:22 That's very helpful. That's very helpful. So there's a path for second half next year data.
37:28 There is a path, but then the key thing right now is that I think we, as you know, we are always very conservative. We will not only share data and opinion once with the agreement FDA is premature for us to make any comment. Here we have a good communication And certainly to be respectful to the regulatory authority's opinion and work together with them is always the most important component in terms of making sure that the drug that we have is safe for the population and is helpful to patients. I think we need to really be respectful. Makes sense.
38:01 Thank you very much. Yeah. I also want to add one more component is that on the last question by Robin about the ethanol, I think that Robin was also asking about with regard to the combination study in terms of abstract to be presented in absolute in the combination study. I think that Rudolph mentioned the study on angiosarcoma. Rudolph, do you want to highlight with regard to the other study on the combination study that Robin probably was asking about?
38:35 Correct. Thank you, Johnson, and sorry for really thinking about the other study. So the study for the PEMBRO study, the presentation in ESMO will include all the initial dose expansion cohort. And that is up around 20 odd patients all together. So you expect to see all the safety and activity data from that initial cohort. And as we indicate, that study we have gone into the expansion cohort of the first indication of lung cancer. And we are currently planning for the second cohort of gastric cancer. So all those initial cohort, initial safety escalation data on safety and activity will be presented in ASMO.
39:30 Allow me to add some more color. I also see one quick question will be whether we're gonna provide data with regard to whether any of these patients were previously anti-PD-1 non-responders. Certainly, those data will be analyzed and will be presented in the external meeting as well with regard to whether the combination of Oropracatexone with anti-PD-1 will have any efficacy in those patients who previously failed to respond to anti-PD-1 monotherapy. I hope we answered the questions of both Uma and Robin. Thank you. Thank you. Our next question comes from the line of Kenan McKay with RBC Capital Markets. Please proceed with your question.
40:15 Thanks for taking the question and really very sad to hear about the resignation. Maybe, Kenan, just help me understand what the goal of this second phase three trial is. It sounds sort of simple on the surface, but I'd love to understand your impression of on whether the FDA's request is for an additional study to understand araxol's neutropenia profile when it's managed with U.S. supportive care, i.e., essentially requesting you to run the same trial but in the U.S. with U.S. supportive care in line with U.S. guidelines, or whether the goal is to determine whether a better risk-reward profile can be achieved versus that which was achieved in the Latin American Phase III trial, which I think could result from sort of a narrowed patient population or entry criteria. And obviously, there's a spectrum of patient sensitivities and risk of severe neutropenia.
41:18 So, you know, potentially just utilizing some biomarkers for recruitment or, you know, ultimately a label, be it age or comorbidities or medical history, which could delineate a patient population that might be at lower risk for severe neutropenia or febrile neutropenia. Can you maybe just sort of help on which of those two scenarios your understanding of the FDA's request is, or if it's something else altogether?
41:48 Go ahead. Canon, the best interpretation we have from the CRL letter and from the Type A meeting, is that the focus of the FDA is in safety data from a U.S. population, from a study that is well conducted. So I think that is where we are for the generator optimal design to address that. Does that help?
42:26 Okay, so it's maybe more like the sort of former, that they're asking for just an understanding of what the safety looks like when it's managed with U.S. standard of care and rigorous supportive care.
42:47 I think it would be my interpretation of the intent in the U.S. population, which basically means using the U.S., medical practice, which they, because the study did not include any U.S. center of those studies, I guess that is the kind of sub-pocket safety data they are looking for. And that is what we are trying to design a study to help them to put additional data.
43:20 Understood. And would it be possible to include either as a you know, subgroup or stratification of enrollment, a portion of patients who would be anticipated to be at lower risk of severe neutropenia, or are there any, you know, biomarkers up front that could enable enrollment of those patients? I only ask because that could provide sort of a a backup shot on goal, if there is still febrile neutropenia in patients at high risk of neutropenia, then that could potentially provide a path to market in patients who are potentially in lower risk, again, if the risk-reward is advantageous for those patients. And, again, obviously, we know that efficacy is important for that.
44:18 What's that? Oh, sorry. Indeed, Canada is a very good question. Indeed, that's what we are looking at with additional analysis, subgroup analysis, and that will all be put into the planning of our proposal to the FDA. So we certainly take all those considerations in our current additional analysis.
44:47 Got it. Maybe just one final question.
44:51 Obviously, we have talked a little bit about sort of backup shots on goal, as I mentioned. With that in mind, what are sort of the next steps for the angiosarcoma program? Can that Phase II trial be expanded into a potentially registrational trial? And have you talked to the FDA yet about a path forward in angiosarcoma?
45:13 That's exactly what we intend to seek input from the FDA on a path forward. Bear in mind angiosarcoma is a treatment, is a disease that has no approved treatment as we speak, and it's a very aggressive therapy. And it is not a common, it's a rare disease, open drug indication. So 43 patients is not a small number. So we intend to talk with the FDA what will represent an approvable package for an indication. So we will be talking with them.
45:51 Got it. Apologies. Oh, go ahead.
45:54 Kenneth, I just want to add some color here. Obviously, you have heard what Rudolph is trying to communicate to everybody with regard to the fact that the current discussion with FDA was positive. FDA was encouraging us to further develop the CD value and like the profile of what we have. But certainly, we have to address the concerns. Now, if the concern is safety, then the study design is only focused on safety. So, therefore, to embark on doing a study without having a good communication, FDA will not be an ideal situation. It's always nice to have an agreed study design, hopefully not a big one, and then that actually will allow us to have an accelerated path going forward with FDA together.
46:40 Now, in relation to that, Mutham also mentioned that there is an alternative path with regard to angiosarcoma. So how to balance these two in such a way that we can satisfy FDA's concern at the same time giving the product the best path forward for approval? I think that we are in a very interesting position. We have more than one path, and then we have multiple opportunities, and we're trying to make the right decision so as to use the capital and time efficiently for this product to be available to patients. I think that summarizes, actually, in a different way, Rudolph's comments. Kevin?
47:20 Absolutely.
47:21 Totally understand. And maybe just a follow-up on the Aura Discovery platform several years ago at your R&D day. You had talked a little bit about next-generation PGB pump inhibitors that could even improve on what we've seen with Insecidor plus Oropeclotaxel. Could you maybe talk about sort of where those are in development in terms of, again, sort of a next-generation Oroxal potentially moving into the clinic? Thanks, and I'm looking forward to hearing more.
47:58 Thank you. Okay, let me address the question. So with regard to the oral pacotaxel, the next generation is a dual inhibitor, inhibiting both the P-gygoprotein as well as the intestinal 3A4 enzyme. So therefore, it's a more such a design for oral docetaxel, in which docetaxel is a 3A4 substrate, a silicone 3A4 substrate. With regard to oral pacotaxel, we do have a tablet formulation, which we can load more of the pachytaxel in the tablet ongoing. The pharmacokinetic studies are already completed, and the data will be presented at the appropriate time. Where we stand right now is that we have a pachytaxel formulation ready and is doing very well, and we believe the profile looks really, really good. And then the further development of our pachytaxel will be more in line with the tablet formulation. Whereas for oral docetaxel, which we already showed very good phase one data, that one will be a perfect substrate when we go to study our second generation, which will have plant extension up to 2034, 2035.
49:06 I mean, I think that is the path forward in terms of developing this first and second generation PTP pump inhibitor. I hope I answered your question, Kenneth.
49:18 Yeah, thanks very much, Johnson and Rudolph.
49:20 Thank you. Thank you, Kevin. Thank you. Ladies and gentlemen, as a reminder, if you'd like to join the question queue, please press star 1 on your telephone keypad. We ask that you please limit yourselves to one question and one follow-up so that we may allow for as many as possible. Our next question comes from the line of Kevin DeJuda with Oppenheimer. Please proceed with your question.
49:47 Hey, thanks for taking my question. Yeah, I'll try to keep this focused. Maybe for Dan, can you talk a little bit about the 503, the HCC program that's moving towards IND, how you're thinking about target product profile there, and just a little bit more with regard to from a structure and profile standpoint, how You know, similar or dissimilar construct is to the two clinical stage programs that you are licensed as part of or that you acquire as part of the acquisition.
50:31 Sure. Hey, Kevin. Thanks for the question. So, for GPC-3, CAR, and KT, we are planning to submit an IMV sometime in 2022. And the target profile of the drug that we're looking for is hopefully that'll serve a balanced risk-reward benefit for these patients. They have very little options for treatment. As you know, some of the first-line and second-line treatments are really undesirable, and the clinical efficacy is really suboptimal. And liver cancer is a very large indication primarily outside the U.S. So, you know, once we have more information on the preclinical data, which is still, you know, ongoing, we'll be able to provide more information about the target profile of this product sometime next year.
51:31 And then I think you highlighted a potential abstract submission for ASH in December. I just want to clarify that that was for Anchor and just more generally. How should we think about the number of patients and scope of that potential update?
51:49 Sure. So, yes, the abstract that we have submitted to ASH is for the Anchorage study. As a reminder, this is an allergenic CD19 CAR NKT cell. When we acquired CureVir back in May, we had disclosed that out of the two patients that were enrolled so far at the lowest dose of 10 times 7 per meter squared. Out of these two patients, we saw one PR and one CR. So, Kevin, expect to see more patient data at ASH, and we're excited to present the safety as well as the efficacy of the ongoing clinical experience that we have so far.
52:35 Thanks for taking my questions. Thank you, Kevin. Thank you, Kevin. Thank you. Our next question comes from the line of Yale Jin with Laidlaw & Company. Please proceed with your question.
52:50 Good morning, and thanks for taking the questions. I just have two here. The first one is you mentioned that you will combine the TCRT and the NKT platform together. I'd just like to get a little bit more color in terms of what specifics you are thinking of.
53:09 Okay.
53:12 So, thank you for the question. So, as you know, we have a high affinity TCR that targets the MYESO antigen that is expressed in a number of different cancers, including lung cancer, head and neck cancer, triple negative breast cancer. So, one scenario could be for us to combine the TCR that we have against MYESO with the NKT cell platform. so that we would have a allogeneic approach targeting NY-ESO, and that we'll be able to, we can test that in a solid tumor indication. Well, we already have some preclinical in vitro and in vivo data to show that these NKG cells could perform quite well when you insert a transgene that that has the TCR sequencing them. And we've been able to show that these NKT cells with the TCRs are able to kill tumors, both in cell lines and also in vivo.
54:22 One other thing I'd like to kind of remind everybody is that NKT cells have a great ability to home to tissue, primarily tumors, and in particular, liver. In humans, it's estimated up to about 10% or 50% of NKT cells are resident within the liver.
54:44 Okay, great. That's very helpful. Maybe one more question here is that you're about to start the TCRT E0A2 trials in this quarter. Could you give us a little bit more color in terms of the study design and the and any other color related.
55:09 Sure. So, this is a Phase I study, primarily, you know, looking for safety. This is a high-affinity T cell targeting against MYESO, and it's an autologous T cell approach. Since we already have some clinical data from our partners, We're actually starting at a very high dose, at a billion cells in our first cohort. And then I think the next dose is 3 billion and then go into 10 billion. And we are looking to enroll patients with the MYESO antigen, for which we have developed a proprietary IHC study, IHC test to enrich for those patients.
55:55 as well as those patients that have the HLA-A2 subtype. There are five different solid tumor indications that we're going after, and they include lung cancer, head and neck cancer, synovial sarcoma, triple negative breast cancer, as well as one last one is the liver cancer.
56:21 Okay, great. And I assume you were looking for the signals as well when you took one point out of this study. Is that correct?
56:31 Absolutely. Yes, there will be, you know, obviously correlative studies, you know, relating to PK, both in the blood and hopefully in the tissue, as well as, you know, the traditional scans and imaging that you would expect for a phase one study of this nature.
56:48 Okay, great. Thanks a lot. I really appreciate it. Thank you. Ladies and gentlemen, this concludes our question-and-answer session. I'll turn the floor back to Dr. Lau for any final comments.
57:02 Thank you, everyone, for joining us today. We'll continue to work with the FDA on a viable path forward for Oropecatexel in metastatic breast cancer. At the same time, we're working on an additional path for Oropecatexel through an orphan drug destination. With the compelling clinical profile demonstrated by this drug candidate, we are also excited by the progress seen in ongoing study of Oropacatexel in combination with Pranpolistamab. Our cell therapy programs are advancing nicely, and we look forward to sharing more clinical data in upcoming scientific meetings. On the commercial front, Kassiri has already received regulatory approvals in both the U.S. and Europe. We have established partnerships in all key geographic areas around the world, which will help bring this variable therapy to more patients in need.
58:01 We appreciate your attention and interest and look forward to providing more updates in the near future. Thank you. Thank you. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.
Follow Athenex Inc into a list and get an email when it puts out news.
Chief Executive Officer
Chief Medical Officer
President, Phoenix Cell Therapy
Chief Operating Officer
Chief Financial Officer
Analyst, Evercore ISI
Analyst, RBC Capital Markets
Analyst, Oppenheimer & Co.
Analyst, Laidlaw & Company